Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of Raltegravir (MK0518) in treatment-experienced HIV
NCT00105157Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Mar 2005
- Primary completion
- Oct 2006
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of raltegravir in human immunodeficiency virus infection (HIV) (4 arms), sponsored by Merck & Co. Primary endpoint: Change From Baseline in Plasma HIV RNA (log10 Copies/mL) at 24 weeks. Started Mar 2005; status: completed.
02
Drugs
raltegravir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT00105157.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00105157.